Zacks Investment Research cut shares of VWR Corporation (NASDAQ:VWR) from a buy rating to a hold rating in a research note published on Monday, July 17th.
According to Zacks, “While we await the second quarter 2017 earnings release within a month or so, VWR has already been trading above the broader industry over the last three months. Geographically, the company recorded balanced growth during the reported quarter. VWR’s Americas and EMEA-APAC sales are currently scaling higher. Management is also looking forward to benefits from the proposed merger with Avantor. The merger is expected to strengthen VWR’s business across the Americas and Europe. However, foreign currency is a major dampener. VWR’s poor margin scenario is also a concern along with intense competition.”
VWR has been the topic of a number of other reports. TheStreet upgraded shares of VWR Corporation from a c rating to a b- rating in a research report on Wednesday, April 19th. William Blair lowered shares of VWR Corporation from an outperform rating to a market perform rating in a research report on Friday, May 5th. Finally, BidaskClub lowered shares of VWR Corporation from a hold rating to a sell rating in a report on Sunday, July 16th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $30.50.
Shares of VWR Corporation (VWR) traded down 0.03% during mid-day trading on Monday, hitting $32.99. The stock had a trading volume of 1,331,492 shares. VWR Corporation has a 52-week low of $24.42 and a 52-week high of $37.25. The stock’s 50-day moving average price is $33.00 and its 200-day moving average price is $30.13. The firm has a market cap of $4.35 billion, a PE ratio of 30.55 and a beta of 1.19.
VWR Corporation (NASDAQ:VWR) last announced its earnings results on Monday, July 31st. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.45 by $0.04. VWR Corporation had a net margin of 3.12% and a return on equity of 15.54%. The business had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same quarter last year, the business earned $0.42 earnings per share. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. On average, analysts anticipate that VWR Corporation will post $1.86 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/08/11/vwr-corporation-vwr-downgraded-by-zacks-investment-research-to-hold-updated-updated-updated.html.
Several large investors have recently added to or reduced their stakes in the stock. FNY Managed Accounts LLC bought a new stake in VWR Corporation during the first quarter worth about $100,000. First Mercantile Trust Co. increased its stake in VWR Corporation by 195.2% in the first quarter. First Mercantile Trust Co. now owns 6,200 shares of the medical research company’s stock worth $175,000 after buying an additional 4,100 shares during the period. Teacher Retirement System of Texas bought a new stake in VWR Corporation during the first quarter worth about $205,000. Neuberger Berman Group LLC bought a new stake in VWR Corporation during the first quarter worth about $219,000. Finally, PNC Financial Services Group Inc. increased its stake in VWR Corporation by 954.2% in the first quarter. PNC Financial Services Group Inc. now owns 8,455 shares of the medical research company’s stock worth $238,000 after buying an additional 7,653 shares during the period.
About VWR Corporation
VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about VWR Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for VWR Corporation and related companies.